Descripción de la empresa
Anika Therapeutics, Inc. operates as a joint preservation company specializing in early intervention orthopedics across the United States, Europe, and international markets. The firm focuses specifically on providing pain management solutions for osteoarthritis through its portfolio of products and services, which include single- and multi-injection hyaluronic acid formulations such as Monovisc and Orthovisc. This business model places the company within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, defining its operational scope around the development and commercialization of pharmaceutical products for specific therapeutic indications. With a market capitalization of $215.16M, an annual revenue of $112.82M, and an employee base of 235, the company presents itself as a mid-sized player within the specialty pharmaceutical landscape. These valuation metrics indicate that Anika Therapeutics maintains a relatively modest scale compared to large-cap peers, reflecting its niche focus on specific orthopedic interventions rather than broad-market drug distribution.
Salud financiera
The company reported a trailing twelve-month revenue of $112.82M alongside a net income of $-9,979,000 and an EBITDA of $-5,471,000. The significant gap between positive revenue and negative net income reveals a cost structure where operating expenses and losses heavily outweigh gross profits, resulting in a net loss that impacts overall profitability. Despite the net loss, the firm generated positive free cash flow of $13.28M, which suggests a degree of financial flexibility allowing the company to fund operations and potentially invest in R&D or debt repayment without immediate reliance on external equity financing. The margin profile highlights distinct challenges in cost control; the gross margin stands at 56.6%, indicating strong pricing power or low cost of goods sold relative to sales, while the operating margin is a narrow 2.1% and the profit margin is negative at -9.6%. The balance sheet shows a cash position of $57.48M against total debt of $26.25M, with a debt-to-equity ratio of 18.30, suggesting a conservative leverage profile given that cash significantly exceeds debt obligations. Liquidity is robust, evidenced by a current ratio of 4.72, which indicates the company holds ample current assets to cover its short-term liabilities with a substantial buffer. Return metrics further illustrate the current financial reality, with a return on equity of -6.7% and a return on assets of -3.5%, revealing that management is currently generating negative returns on both shareholder capital and the asset base.
Evaluación de valoración
Valuation metrics for Anika Therapeutics present a complex picture due to the absence of earnings, indicated by a trailing P/E ratio of N/A and a forward P/E of 37.30. The disparity between the non-existent trailing P/E and the forward P/E implies that the market is pricing in future earnings expectations that have not yet been realized in historical performance. Relative to its book value, the stock trades at a price-to-book ratio of 1.44, suggesting a moderate market premium over the company's net asset value despite current losses. Alternative valuation measures provide additional context; the price-to-sales ratio is 1.91 and the EV/EBITDA is -30.84, indicating that investors are valuing the company primarily on revenue generation and cash flow potential rather than current earnings power. In terms of trading range, the stock has a 52-week high of $15.18 and a 52-week low of $7.87. Without a specific current price provided in the facts, the valuation range establishes a volatility corridor within which the stock price fluctuates over the past year. The beta value of 0.28 indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the S&P 500 during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is recorded at 0.0%, while earnings growth is listed as N/A due to the negative net income position. The stagnation in revenue growth combined with negative earnings implies that the company is not currently expanding its top line or improving its bottom line at a pace that would drive traditional earnings-based growth metrics. As a non-dividend payer, the company does not distribute income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This structure implies that the company retains all earnings, or rather, absorbs all losses, with no portion allocated to shareholder distributions, focusing instead on operational survival and potential future growth initiatives. Consequently, the overall growth and income profile is characterized by zero revenue expansion, negative profitability, no dividend distribution, and a low-beta stock price that offers stability but limited income generation for investors seeking current yield.